ADS 012
Alternative Names: ADS-012; ADS00X; ADS0XXLatest Information Update: 17 Nov 2022
At a glance
- Originator Adiso Therapeutics
- Class Anti-inflammatories; Bacteria
- Mechanism of Action Bacteria replacements; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Inflammation
Most Recent Events
- 15 Nov 2022 Early research in Inflammation in USA (unspecified route) (Adiso Therapeutics pipeline, November 2022)
- 15 Nov 2022 Preclinical trials in Inflammation in USA (unspecified route) (Adiso Therapeutics pipeline, November 2022)